Management Tips | CML Alliance
For Healthcare Professionals Outside the US
Send To a FriendPrint This PageChange Text Size

Management TipsManagement Tips

While TASIGNA® and GLIVEC® are both generally well tolerated, as with all treatments there are risks of adverse events. Management may not be possible in all patients—some patients may require dose adjustment, interruption, or discontinuation. The following management tips are provided for your consideration, to help with the management of some common side effects that have been associated with either TASIGNA® or GLIVEC®. For additional information, please click here to view the European SMPCs.

 
Management Tips
Frequently Asked Questions

Next: CML Resources: Patient & Physician Resources

Note: Before prescribing, please read full European Summary of Product Characteristics.

References

  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2007.
  2. GLIVEC® (imatinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; April 2010.